- Tyra Biosciences press release ( NASDAQ: TYRA ): Q3 GAAP EPS of -$0.30 beats by $0.11 .
- Third quarter 2022 net loss was $12.5 million compared to $6.6 million for the same period in 2021.
- Third quarter 2022 research and development expenses were $10.9 million compared to $5.5 million for the same period in 2021.
- Third quarter 2022 general and administrative expenses were $2.7 million compared to $1.2 million for the same period in 2021.
- As of September 30, 2022, TYRA had cash and cash equivalents of $263.2 million.
For further details see:
Tyra Biosciences GAAP EPS of -$0.30 beats by $0.11